Skip to main content

180 Life Sciences Corp

For the period ended Dec 27, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Dec 27, 2024 · Filed Nov 12, 2024

FRMM$3.040.0%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

DEF 14A 1 ea0220686-def14a_180life.htm DEFINITIVE PROXY STATEMENT

**UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant☒
Filed by party other than the registrant☐

Check the appropriate box:

☐Preliminary Proxy Statement
☐Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
☒Definitive Proxy Statement
☐Definitive additional materials
☐Soliciting material under Rule 14a-12

**180 LIFE SCIENCES CORP.

**(Name of Registrant as Specified in Charter)

Payment of Filing Fee (Check all boxes that apply):

☒No fee required
☐Fee paid previously with preliminary materials
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

3000 El Camino Rd., Bldg. 4, Suite 200

Palo Alto, California 94306

November 12, 2024

To Our Stockholders:

The Board of Directors (“Board”) and officers of 180 Life Sciences Corp., a Delaware corporation (the “Company”), join us in extending to you a cordial invitation to attend the 2024 annual meeting of our stockholders, which we refer to as the annual meeting or the Meeting, to be held (subject to postponement(s) or adjournment(s) thereof):

Date:December 27, 2024
Time:1:00 p.m. Pacific Time
Virtual Meeting Site:https://agm.issuerdirect.com/ATNF

You will not be able to attend the annual meeting physically. The annual meeting will be held via an audio teleconference. Stockholders may attend, vote and submit questions during the annual meeting via the Internet by logging in athttps://agm.issuerdirect.com/ATNF, with your Control ID and Request ID, and thereafter following the instructions to join the virtual meeting. In addition to voting by submitting your proxy prior to the annual meeting and/or voting online as discussed herein, you also will be able to vote your shares electronically during the annual meeting with your Request ID. Details regarding the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.

As permitted by the rules of the Securities and Exchange Commission (the “SEC” or the “Commission”), we have provided access to our proxy materials over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials, or E-proxy notice, on or about November 12, 2024, to our stockholders of record as of the close of business on November 12, 2024. The E-proxy notice contains instructions for your use of this process, including how to access our proxy statement and annual report and how to authorize your proxy to vote online. In addition, the E-proxy notice contains instructions on how you may receive a paper copy of the proxy statement and annual report or elect to receive your proxy statement and annual report over the Internet. We believe these rules allow us to provide you with the information you need while lowering the costs of delivery and reducing the environmental impact of the annual meeting.

The Notice of Annual Meeting and Proxy Statement, is also available athttps://www.iproxydirect.com/ATNF. This website also includes copies of our Annual Report on Form 10-K for the year ended December 31, 2023, which we refer to as the annual report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.

In connection with the annual meeting, you will be asked to consider and vote on certain proposals, which are more fully described in the accompanying proxy statement. Whether or not you plan to attend the annual meeting, we urge you to read the proxy statement (and any documents incorporated into the proxy statement by reference) and consider such information carefully before voting. The attached Notice of Annual Meeting and the Proxy Statement describe the business to be considered and acted upon by the stockholders at the annual meeting. Please review these materials and vote your shares.

Your vote is very important. Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your proxy by mail, fax, Internet or telephone as soon as possible to make sure that your shares are represented at the annual meeting. If you hold your shares of Company stock in “street name” through a bank, broker, or other nominee, you must vote in accordance with the voting instructions provided to you by such bank, broker, or other nominee, which include instructions for voting by Internet or telephone.

Our Board of Directors encourages your participation in 180 Life Sciences Corp.’s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.

We look forward to seeing you on December 27, 2024. Your vote and participation in our governance is very important to us.

Sincerely,

/s/ Blair Jordan

Blair Jordan

Interim Chief Executive Officer and Director

Important Notice Regarding the Availability of Proxy Materials for the Virtual Annual Meeting of Stockholders to Be Held on December 27, 2024.

Our proxy statement and Annual Report on Form 10-K for the year ended December 31, 2023 are available at the following cookies-free website that can be accessed anonymously:https://agm.issuerdirect.com/ATNF. Stockholders may also vote prior to the meeting atwww.iproxydirect.com/ATNF.

**180 LIFE SCIENCES CORP.

**3000 El Camino Rd., Bldg. 4, Suite 200

Palo Alto, California 94306

**NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON DECEMBER 27, 2024

To the Stockholders of 180 Life Sciences Corp.:

We are pleased to provide you notice of, and to invite you to attend, the 2024 annual meeting of the stockholders of 180 Life Sciences Corp., a Delaware corporation (“180 Life”, the “Company”, “we” and “us”), which will be held on December 27, 2024, at 1:00 p.m., Pacific Time (subject to postponement(s) or adjournment(s) thereof), which we refer to as the annual meeting, or the “Meeting”. The meeting will be held virtually via live audio webcast athttps://agm.issuerdirect.com/ATNF. See also “Instructions For The Virtual Annual Meeting”, beginning on page 1. The annual meeting is being held for the following purposes:

1.To elect three Class II directors to the Board of Directors (the “Board”) each to serve a term of two years and until their respective successors have been elected and qualified, or until such director’s resignation or removal. The Board has nominated for re-election the following incumbent Class II directors: Blair Jordan, Ryan Smith and Omar Jimenez.
2.To approve the adoption of the Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. The Board of Directors recommends that you approve and ratify the Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan.
3.To approve an advisory resolution on Named Executive Officer compensation. The Board of Directors recommends that you approve and ratify executive compensation.
4.To approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the conversion of Series B Convertible Preferred Stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b). The Board of Directors recommends that you approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the conversion of Series B Convertible Preferred Stock for purposes of complying with Nasdaq Listing Rules 5635(a) and (b).
5.To approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the exercise of outstanding warrants to purchase shares of common stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b). The Board of Directors recommends that you approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the exercise of outstanding warrants to purchase shares of common stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b).
6.To ratify the appointment of M&K CPAs, PLLC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2024. The Board of Directors recommends that you approve and ratify the appointment of M&K CPAs, PLLC as the Company’s independent auditors for the fiscal year ending December 31, 2024.
7.To transact such other business as may properly come before the annual meeting.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR ALL” FOR PROPOSAL ONE, AND “FOR” PROPOSALS TWO, THREE, FOUR, FIVE AND SIX.

Any action may be taken on any one of the foregoing proposals at the Meeting on the date specified above or on any date or dates to which the Meeting may be postponed or adjourned. We do not expect to transact any other business at the annual meeting. Our Board of Directors has fixed the close of business on October 31, 2024, as the record date for determining those stockholders entitled to vote at the annual meeting and any adjournment or postponement thereof. Accordingly, only common and preferred stock stockholders of record at the close of business on that date are entitled to notice of, and to vote at, the annual meeting.

We cordially invite you to attend the annual meeting. However, to ensure your representation at the annual meeting, please authorize the individuals named on your proxy card to vote your shares by calling the toll-free telephone number, faxing your proxy card or by using the Internet as described in the instructions included with your proxy card or voting instruction card. Alternatively, if you received a paper copy of the proxy card by mail, please complete, date, sign and promptly return the proxy card. This will not prevent you from voting at the meeting, but will help to secure a quorum and avoid added solicitation costs. If your shares are held in “street name” by your broker or other nominee, only that holder can vote your shares and the vote cannot be cast unless you provide instructions to your broker. You should follow the directions provided by your broker regarding how to instruct your broker to vote your shares. Your proxy may be revoked at any time before it is voted. Please review the proxy statement accompanying this notice for more complete information regarding the matters to be voted on at the meeting.

The enclosed proxy statement, notice of the availability of which is first being mailed to stockholders on or about November 12, 2024, is also available athttps://www.iproxydirect.com/ATNF. This website also includes our Annual Report on Form 10-K for the year ended December 31, 2023, which we refer to as the 2023 Annual Report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.

Even if you plan to attend the annual meeting, we request that you submit a proxy by following the instructions on your proxy card as soon as possible and thus ensure that your shares will be represented at the annual meeting if you are unable to attend.

If you have any questions or require any assistance with voting your shares, please contact our proxy agent, Issuer Direct Corporation at (919) 481-4000, or 1-866-752-VOTE (8683).

By Order of the Board of Directors:

/s/ Blair Jordan

Blair Jordan

Interim Chief Executive Officer and Director

Palo Alto, California

November 12, 2024

IMPORTANT: WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ASK YOU TO VOTE BY TELEPHONE, MAIL, FAX OR ON THE INTERNET USING THE INSTRUCTIONS ON THE PROXY CARD.

TABLE OF CONTENTS

General Information1
Information Contained in this Proxy Statement1
Instructions For The Virtual Annual Meeting1
Questions During the Annual Meeting1
Technical Difficulties or Trouble Accessing the Virtual Meeting Website2
Important Notice Regarding the Availability of Proxy Materials2
Record Date and Shares Entitled to Vote2
Voting Process3
Providing and Revoking Proxies3
Meeting Time and Location: Virtual Annual Meeting3
Conduct at the Meeting4
Voting Requirements for Each of the Proposals4
Quorum5
Board of Directors Voting Recommendations5
Mailing Costs and Solicitation of Proxies6
Inspector of Voting6
Stockholders Entitled to Vote at the Meeting6
Voting Instructions6
Confidential Voting6
Stockholder of Record and Shares Held in Brokerage Accounts6
Multiple Stockholders Sharing the Same Address7
Voting Results7
Company Mailing Address7
Other Matters7
Background of the Company8
Reverse Stock SplitS8
Definitions8
Forward-Looking Statements and Website Links9
Incorporation by Reference9
References to Additional Information9
Voting Rights and Principal Stockholders9
Security Ownership of Management and Certain Beneficial Owners and Management10
Change of Control11
Corporate Governance11
Board Leadership Structure11
Risk Oversight11
Family Relationships12
Arrangements between Officers and Directors12
Other Directorships12
Involvement in Certain Legal Proceedings13
Board of Directors Meetings13
Board Committee Membership13
Audit Committee14
Compensation Committee15
Compensation Committee Interlocks and Insider Participation15
Nominating and Governance Committee15
Director Independence16

i

Board Diversity Matrix17
Website Availability of Documents17
Stockholder Communications with the Board of Directors18
Lead Independent Director18
Executive Sessions of the Board of Directors18
Code of Ethics18
Policy on Equity Ownership18
Insider Trading/Anti-Hedging Policies19
Report of Audit Committee19
Audit Committee Report20
Information About Our Executive Officers and Directors21
Executive Officers21
Classified Board of Directors21
Director Nominees22
Director Qualifications24
Director Whose Term Extends Beyond the 2024 Annual Meeting24
Executive and Director Compensation25
Summary Executive Compensation Table25
Current Compensation Agreements27
Jordan Consulting Agreement27
Prior Employment Agreements28
James N. Woody 180 Employment Agreement28
James N. Woody Amended and Restated Employment Agreement (terminated); and Separation Agreement28
Dr. Rothbard’s Employment Agreement (terminated); and Separation Agreement29
Ozan Pamir Katexco Employment Agreement (Terminated)30
Ozan Pamir Company Employment Agreement (Terminated)30
Quan Anh Vu Executive Employment Agreement (terminated); and Separation Agreement31
Description of Material Consulting Agreements32
Service Agreement with Prof. Sir Marc Feldmann (former Co-Executive Chairman)(Terminated)32
Consultancy Agreement and Consulting Agreement with Prof. Lawrence Steinman33
Prof. Jagdeep Nanchahal Consulting Agreement34
Salary Increases and Temporary Salary and Compensation Accruals36
Payment of Back Pay; 2021 Bonuses and Increases in Salaries38
2024 Accruals38
2022, 2023 and 2024 Bonuses38
Pay Versus Performance39
Relationship Between “Compensation Actually Paid” and Performance41
Compensation Actually Paid and Net Loss41
Compensation Actually Paid and Cumulative TSR41
Outstanding Equity Awards at Fiscal Year End42
Potential Payments Upon Termination42
Director Compensation42
Board of Director Fees44
Equity Compensation Plan Information45
2020 Omnibus Incentive Plan45
2022 Omnibus Incentive Plan45
Certain Relationships and Related Party Transactions46
Related Party Agreements46
360 Life Sciences Corp. Agreement - Related Party (Acquisition of ReFormation Pharmaceuticals Corp.)46
Notice of Acceleration46

ii

Service Agreement with Prof. Sir Marc Feldmann47
Prof. Jagdeep Nanchahal Consulting Agreement47
Prof. Lawrence Steinman Consultancy Agreement and Consulting Agreement47
General and Administrative - Related Parties47
Interest Expense on Loans Payable47
Interest Income - Related Parties47
Accrued Expenses - Related Parties47
Research and Development Expenses – Related Parties48
Accounts Payable – Related Parties48
Registration Rights48
Related Party Litigation49
Indemnification Agreements52
Related Party Transaction Policy52
Delinquent Section 16(a) Reports53
Summary of September 2024 Asset Purchase Agreement; Series B Convertible Preferred Stock and Warrants54
Background54
Series B Convertible Preferred Stock55
Common Stock Purchase Warrants56
Proposal 1 Election of Directors57
General57
General Director Qualifications57
What Vote Is Required To Elect the Director Nominees57
PROPOSAL 2 ADOPTION OF THE THIRD AMENDMENT TO THE 180 LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN58
General58
Background and Purpose of the Amended Plan59
Current Overview of Outstanding Equity Information59
Summary of the Material Terms of the Amended Plan59
Federal Income Tax Consequences64
Unanimous Recommendation of the Board of Directors; Vote Required66
Proposal 3 Approval of an Advisory Resolution on Named Executive Officer Compensation67
General67
Vote Required67

iii

Proposal 4 for Purposes of Complying with Nasdaq Listing Rules 5635(a) and (B), to Approve the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Upon the Conversion of Series B Convertible Preferred Stock68
Background68
Reasons for Stockholder Approval68
Consequences of Not Approving the Proposal69
Description of the Common Stock that May be Issued69
Resale Limitations69
Vote Required69
Proposal 5 for Purposes of Complying with Nasdaq Listing Rules 5635(a) and (B), to Approve the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Upon the Exercise of Warrants to Purchase Up to 3,000,000 Shares of Common Stock70
Background70
Reasons for Stockholder Approval70
Consequences of Not Approving the Proposal70
Description of the Common Stock that May be Issued70
Resale Limitations70
Vote Required70
Proposal 6 Ratification of Appointment of Auditors71
Change in Independent Registered Public Accounting Firm71
General72
Principal Accounting Fees and Services72
Audit Committee Policy for Pre-approval of Independent Registered Public Accounting Firm Services73
Pre-Approval Policies73
Vote Required73
OTHER MATTERS74
Proxy Statement Proposals74
Other Proposals and Nominations74
Additional Filings75
Other Matters to be Presented at the Annual Meeting75
Interest of Certain Persons in or Opposition to Matters to Be Acted Upon:75
Company Contact Information75

Appendixes:

**Appendix A —**Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan

Appendix B — Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan

iv

**PROXY STATEMENT

FOR 2024 ANNUAL MEETING OF STOCKHOLDERS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.